Novo Nordisk A/S (NYSE:NVO) Shares Acquired by Financial Partners Group LLC

Financial Partners Group LLC boosted its holdings in Novo Nordisk A/S (NYSE:NVO) by 31.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 14,384 shares of the company’s stock after acquiring an additional 3,438 shares during the period. Financial Partners Group LLC’s holdings in Novo Nordisk A/S were worth $1,237,000 at the end of the most recent quarter.

Several other institutional investors also recently made changes to their positions in the stock. Xponance Inc. increased its position in Novo Nordisk A/S by 27.6% in the second quarter. Xponance Inc. now owns 2,665 shares of the company’s stock worth $380,000 after buying an additional 576 shares during the period. Insigneo Advisory Services LLC boosted its stake in Novo Nordisk A/S by 1.0% during the 2nd quarter. Insigneo Advisory Services LLC now owns 10,693 shares of the company’s stock valued at $1,526,000 after purchasing an additional 108 shares during the period. Fred Alger Management LLC grew its position in Novo Nordisk A/S by 38.4% in the 2nd quarter. Fred Alger Management LLC now owns 54,493 shares of the company’s stock worth $7,778,000 after purchasing an additional 15,129 shares during the last quarter. AlTi Global Inc. increased its stake in shares of Novo Nordisk A/S by 30.4% in the second quarter. AlTi Global Inc. now owns 5,647 shares of the company’s stock valued at $806,000 after purchasing an additional 1,318 shares during the period. Finally, Armistice Capital LLC raised its holdings in shares of Novo Nordisk A/S by 36.0% during the second quarter. Armistice Capital LLC now owns 544,000 shares of the company’s stock valued at $77,651,000 after buying an additional 144,000 shares during the last quarter. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Trading Up 1.0 %

Shares of NVO stock opened at $81.36 on Friday. The stock has a 50-day simple moving average of $96.10 and a 200 day simple moving average of $115.79. The stock has a market capitalization of $365.09 billion, a P/E ratio of 26.33, a P/E/G ratio of 0.90 and a beta of 0.45. Novo Nordisk A/S has a fifty-two week low of $78.17 and a fifty-two week high of $148.15. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on NVO. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. BMO Capital Markets decreased their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. Finally, Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Novo Nordisk A/S currently has a consensus rating of “Buy” and an average price target of $145.25.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.